Bullfrog AI, LIBD collaboration identifies potential drug targets

BullFrog AI announced significant advancements in its collaboration with the Lieber Institute for Brain Development, LIBD, including the identification of potential drug targets for multiple neuropsychiatric conditions. BullFrog AI and LIBD have made remarkable progress in identifying novel subgroups between and within neuropsychiatric disorders, including major depression, schizophrenia, and bipolar disorder. Utilizing a combination of ensemble machine learning, generative AI, and graph analytics, the team has successfully clustered patients by expression levels of gene isoforms across multiple brain regions.